Polimorfismos genéticos y farmacogenética en la artritis reumatoide

Evans, 1999, Pharmacogenomics: Translating functional genomics into rational therapeutics, Science, 286, 487, 10.1126/science.286.5439.487 Silman, 1993, Twin concordance rates for rheumatoid arthritis: Results from a nationwide study, Br J Rheumatol, 32, 903, 10.1093/rheumatology/32.10.903 Cornelis, 1997, Rheumatoid arthritis genome scan and pretative autoimmunity locus, Arthritis Reum, 40, S329 Pierik, 2006, Pharmacogenetics in inflammatory bowel disease, World J Gastroenterol, 12, 3657, 10.3748/wjg.v12.i23.3657 Nepom, 1998, Major histocompatibility complex-directed susceptibility to rheumatoid arthritis, Adv Immunol, 68, 315, 10.1016/S0065-2776(08)60563-5 Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annu Rev Immunol, 14, 397, 10.1146/annurev.immunol.14.1.397 Deighton, 1989, The contribution of HLA to rheumatoid arthritis, Clin Genet, 36, 178, 10.1111/j.1399-0004.1989.tb03185.x Gregersen, 1987, The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis, Arthritis Rheum, 30, 1205, 10.1002/art.1780301102 McGregor, 1995, HLA-DRB1 *0401/0404 genotype and rheumatoid arthritis: Increased association in men, young age at onset, and disease severity, J Rheumatol, 22, 1032 Reveille, 2005, Genetic studies in the rheumatic diseases: Present status and implications for the future, J Rheumatol, 72, 10 Martínez, 2004, Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients, Arthritis Rheum, 50, 1077, 10.1002/art.20154 Padyukov, 2003, Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis, Ann Rheum Dis, 62, 526, 10.1136/ard.62.6.526 Brennan, 1992, TNF alpha -a pivotal role in rheumatoid arthritis?, Br J Rheumatol, 31, 293, 10.1093/rheumatology/31.5.293 Smith, 1994, The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death, Cell, 76, 959, 10.1016/0092-8674(94)90372-7 Vassalli, 1992, The pathophysiology of tumor necrosis factors, Annu Rev Immunol, 10, 411, 10.1146/annurev.iy.10.040192.002211 Verweij, 1999, Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis, Ann Rheum Dis, 58, I20, 10.1136/ard.58.2008.i20 Campbell, 1993, Map of the human MHC, Immunol Today, 14, 349, 10.1016/0167-5699(93)90234-C Wilson, 1993, An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles, J Exp Med, 177, 557, 10.1084/jem.177.2.557 Jacob, 1990, Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus, Proc Natl Acad Sci USA, 87, 1233, 10.1073/pnas.87.3.1233 Brinkman, 1997, Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: Association with susceptibility to, or severity of disease?, Br J Rheumatol, 36, 516, 10.1093/rheumatology/36.5.516 Udalova, 2000, Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region, Mol Cell Biol, 20, 9113, 10.1128/MCB.20.24.9113-9119.2000 Newton, 2003, The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype, Arthritis Rheum, 48, 90, 10.1002/art.10719 Kuo, 2005, TNF-857T, a genetic risk marker for acute anterior uveitis, Invest Opthalmol Vis Sci, 46, 1565, 10.1167/iovs.04-0932 Akman, 2006, TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease, Br J Dermatol, 155, 350, 10.1111/j.1365-2133.2006.07348.x Smerdel, 2002, A gene in the telomeric HLA complex distinct from HLA-A is involved in predisposition to juvenile idiopathic arthritis, Arthritis Rheum, 46, 1614, 10.1002/art.10337 Santee, 1996, Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization, J Biol Chem, 271, 21151, 10.1074/jbc.271.35.21151 Ranganathan, 2005, Pharmacogenetics of tumor necrosis factor antagonists in rheumatoid arthritis, Pharmacogenomics, 6, 481, 10.2217/14622416.6.5.481 Udalova, 1993, Highly informative typing of the human TNF locus using six adjacent polymorphic markers, Genomics, 16, 180, 10.1006/geno.1993.1156 Mulcahy, 1996, Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis, Am J Hum Genet, 59, 676 Van den Berg, 2000, Arguments for interleukin 1 as a target in chronic arthritis, Ann Rheum Dis, 59, I81, 10.1136/ard.59.suppl_1.i81 Nicklin, 1994, A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes, Genomics, 19, 382, 10.1006/geno.1994.1076 Cox, 1998, An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers, Am J Hum Genet, 62, 1180, 10.1086/301817 McDowell, 1995, A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism, Arthritis Rheum, 38, 221, 10.1002/art.1780380210 Van den Velden, 1993, Amino acid dimorphism in IL1A is detectable by PCR amplification, Hum Mol Genet, 2, 1753, 10.1093/hmg/2.10.1753-a Di Giovine, 1992, Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta), Hum Mol Genet, 1, 450, 10.1093/hmg/1.6.450 Pociot, 1992, A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro, Eur J Clin Invest, 22, 396, 10.1111/j.1365-2362.1992.tb01480.x Di Giovine FS, Camp NJ, Cox A. Detection and population analysis of IL-1 and TNF gene polymorphisms. In: Balkwill F, editor. Cytokine Molecular Biology. Oxford: Oxford University Press; 2000. p. 21–46. Cantagrel, 1999, Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis, Arthritis Rheum, 42, 1093, 10.1002/1529-0131(199906)42:6<1093::AID-ANR5>3.0.CO;2-P Buchs, 2001, IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: Interaction with their plasma levels, Genes Immun, 2, 222, 10.1038/sj.gene.6363766 Santtila, 1998, Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro, Scand J Immunol, 47, 195, 10.1046/j.1365-3083.1998.00300.x Hulkkonen, 2000, A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals, Eur Cytokine Netw, 11, 251 Dominici, 2002, Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-2 alpha, Immunogenetics, 54, 82, 10.1007/s00251-002-0445-9 Whyte, 2000, Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms, Am J Respir Crit Care Med, 162, 755, 10.1164/ajrccm.162.2.9909053 Feldmann, 2001, The role of TNF alpha and IL-1 in rheumatoid arthritis, Curr Dir Autoimmun, 3, 188, 10.1159/000060522 Uson, 1997, Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies, J Rheumatol, 24, 2069 Xing, 1998, IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses, J Clin Invest, 101, 311, 10.1172/JCI1368 Tilg, 1994, Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55, Blood, 83, 113, 10.1182/blood.V83.1.113.113 Pascual, 2000, IL-6 promoter polymorphisms in rheumatoid arthritis, Genes Immun, 1, 338, 10.1038/sj.gene.6363677 Fishman, 1998, The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis, J Clin Invest, 102, 1369, 10.1172/JCI2629 Martínez, 2003, Genetic polymorphisms in Spanish rheumatoid arthritis patients: An association and linkage study, Genes Immun, 4, 117, 10.1038/sj.gene.6363931 Chernoff, 1995, A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses, J Immunol, 154, 5492, 10.4049/jimmunol.154.10.5492 Turner, 1997, An investigation of polymorphism in the interleukin-10 gene promoter, Eur J Immunogenet, 24, 1, 10.1111/j.1365-2370.1997.tb00001.x Braun, 1996, Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and its influence on the regulation of TNF-alpha production, Neurosci Lett, 215, 75 Padyukov, 2004, Polymorphism in promoter region of IL-10 gene is associated with rheumatoid arthritis in women, J Rheumatol, 31, 422 Ranganathan, 2006, Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis, Arthritis Rheum, 54, 1366, 10.1002/art.21762 Dervieux, 2003, Single nucleotide polymorphisms (SNPs) in the folate/purine synthesis pathway predict methotrexate′s effect in rheumatoid arthritis, Arthritis Reum, 48, S438 Pawlik, 2004, The MDR1 3435 polymorphism in patients with rheumatoid arthritis, Int J Clin Pharmacol Ther, 42, 496, 10.5414/CPP42496 Kang, 1988, Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductasa, Am J Hum Genet, 43, 414 Haagsma, 1999, Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis, Ann Rheum Dis, 58, 79, 10.1136/ard.58.2.79 Urano, 2002, Polymorphisms in the methylenetetrahydrofolate reductasa gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses, Pharmacogenetics, 12, 183, 10.1097/00008571-200204000-00002 Taniguchi, 2007, Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A proposal for prospective pharmacogenomic study in clinical practice, Pharmacogenet Genom, 17, 383, 10.1097/01.fpc.0000236326.80809.b1 Dervieux, 2006, Pharmacogenetic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis, Arthritis Rheum, 54, 3095, 10.1002/art.22129 Berkun, 2004, Methotrexate related adverse effects in patients with rheumatoid artritis are associated with the A1298C polymorphism of the MTHFR gene, Ann Rheum Dis, 63, 1227, 10.1136/ard.2003.016337 Kumagai, 2003, Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductasa genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis, Intl J Mol Med, 11, 593 Herrlinger, 2005, The pharmacogenetics of methotrexate in inflammatory bowel disease, Pharmacogenet Genom, 15, 705, 10.1097/01.fpc.0000172242.19675.33 Wessels, 2007, A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis, Arthritis Rheum, 56, 1765, 10.1002/art.22640 Horie, 1995, Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase, Cell Struct Funct, 20, 191, 10.1247/csf.20.191 DiPaolo, 2004, The role of thymidylate synthase as a molecular biomarker, Clin Cancer Res, 10, 411, 10.1158/1078-0432.CCR-1198-03 Ulrich, 2000, Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene, Cancer Epidemiol Biomarkers Prev, 9, 1381 Grzybowska, 2001, Regulatory functions of 3UTRs, Biochem Biophys Res Commun, 288, 291, 10.1006/bbrc.2001.5738 Dervieux, 2004, Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis, Arthritis Rheum, 50, 2766, 10.1002/art.20460 Rains, 1995, Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis, Drugs, 50, 137, 10.2165/00003495-199550010-00009 Pullar, 1986, Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review, Drugs, 32, 54, 10.2165/00003495-198600321-00011 Wadelius, 2000, Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis, Pharmacogenetics, 10, 35, 10.1097/00008571-200002000-00005 Tanaka, 2002, Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene, J Rheumatol, 29, 2492 Ranganathan, 2005, Pharmacogenetics of therapies in rheumatoid arthritis, Drugs today, 41, 799, 10.1358/dot.2005.41.12.939959 Krynetski, 1996, Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms, Pharmacogenetics, 6, 279, 10.1097/00008571-199608000-00001 Tai, 1997, Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) ancoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity, Proc Natl Acad Sci USA, 94, 6444, 10.1073/pnas.94.12.6444 Corominas, 2003, Is thiopurine methyltransferase genetic polymorphism a major factor for with drawal of azathioprine in rheumatoid arthritis patients?, Rheumatology, 42, 40, 10.1093/rheumatology/keg028 Genovese, 2002, Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes, Arthritis Rheum, 46, 1443, 10.1002/art.10308 Keystone, 2004, Arthritis Rheum, 50, 1400, 10.1002/art.20217 Greenberg, 2007, The promise of pharmacogenetics to TNF antagonists in rheumatoid arthritis, Bulletin of the NYU Hospital for Joint Diseases, 65, 139 Ferraccioli, 2003, The possible clinical application of pharmacogenetics in rheumatology, J Rheumatol, 30, 2517 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 Bouma, 1996, Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease, Scand J Immunol, 43, 456, 10.1046/j.1365-3083.1996.d01-65.x Callan, 2004, Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients, Curr Opin Rheumatol, 16, 399, 10.1097/01.bor.0000126149.96627.82 Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W Baecklund, 1998, Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study, BMJ, 317, 180, 10.1136/bmj.317.7152.180 Emery, 2001, Changes in Pro-MMP-1 in relation to standard measures of disease activity over a 6-month treatment period with adalimumab (D2E7) in rheumatoid arthritis, Arthritis Reum, 44, 215 Bresnihan, 1998, Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist, Arthritis Rheum, 41, 2196, 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2 Cohen, 2002, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 614, 10.1002/art.10141 Fleischmann, 2003, Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial, Arthritis Rheum, 48, 927, 10.1002/art.10870 Guignard, 2007, Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: A case report, Clin Exp Rheumatol, 25, 758 Kalliolias, 2008, The future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis, Expert Opin Investig Drugs, 17, 349, 10.1517/13543784.17.3.349 Criswell, 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept, Arthritis Rheum, 50, 2750, 10.1002/art.20469 Walsh, 2003, An integrated haplotype map of the human major histocompatibility complex, Am J Hum Genet, 73, 580, 10.1086/378101 Kang, 2005, The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis, Rheumatology (Oxford), 44, 547, 10.1093/rheumatology/keh550 Fabris, 2002, Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid artritis, J Rheumatol, 29, 1847 Schotte, 2005, Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis, Ann Rheum Dis, 64, 575, 10.1136/ard.2004.027672 Mugnier, 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis, Arthritis Rheum, 48, 1849, 10.1002/art.11168 Cuchacovich, 2004, Tumor necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis, Scand J Rheumatol, 33, 228, 10.1080/03009740410005863 Fonseca, 2005, Polymorphism at position-308 of the tumor necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics, Ann Rheum Dis, 64, 793, 10.1136/ard.2004.028167 Pinto, 2008, Polymorphisms in genes encoding TNF-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis, J Rheumatol, 35, 177 Camp, 2005, Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis, Genes Immun, 6, 467, 10.1038/sj.gene.6364228 Arnett, 1998, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Reum, 31, 315, 10.1002/art.1780310302 Choy, 2001, Cytokine pathways and joint inflammation in rheumatoid arthritis, N Engl J Med, 344, 907, 10.1056/NEJM200103223441207 Bridges, 1999, The genetics of rheumatoid arthritis: Influences on susceptibility, severity, and treatment response, Curr Rheumatol Rep, 1, 164, 10.1007/s11926-999-0014-4 Evans, 2003, Pharmacogenomics-drug disposition, drug targets, and side effects, N Eng J Med, 348, 538, 10.1056/NEJMra020526 Lequerré, 2006, Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis, Arthritis Res Ther, 8, R105, 10.1186/ar1990 Hirschhorn, 2002, A comprenhensive review of genetic association studies, Genet Med, 4, 45, 10.1097/00125817-200203000-00002